AML
Newly diagnosed AML
a. If CBF positive--> add GO to 7+3
b. FLT 3 mutation positive--> add midostaurin to 7+3 ( age 18-60 yr per study, not per FDA label)
c. Secondary AML or t-AML--> use CPX351( liposomal cytarabine with daunorubicin 5:1 ratio) CPX-351 had a higher median OS than 7 + 3 (9.56 vs 5.95 months
Elderly AML not fit for intensive treatment
Venetoclax with Aza or decitabine
Low dose cytarabine with venetoclax
IDH1 (ivosedinib) and IDH2 inhibitor Enasedinib can be used in this space although unclear if better than venetoclax based therapy
No comments:
Post a Comment